Incoming HIV virion-derived Gag Spacer Peptide 2 (p1) is a target of effective CD8+ T cell antiviral responses

Hongbing Yang(Nuffield Orthopaedic Centre), Fleur Hudson(Royal Free London NHS Foundation Trust), Aminata Sy, Ian Weller(University College London), Tomáš Hanke(University of Oxford), Geraldine M. Gillespie(MRC Human Immunology Unit), Sarah Pett(MRC Clinical Trials Unit at UCL), Andrew Lovell(Immunocore (United Kingdom)), Peter Sasieni(Queen Mary University of London), Samandhy Cedeño(IrsiCaixa), Rachel Bennett, Jane Anderson(Baylor College of Medicine), Andrew Knox(Immunocore (United Kingdom)), Michelle Gabrielle, Helen Brown(Princess Alexandra Hospital), Beatriz Mothe(Universitat de Vic - Universitat Central de Catalunya), Angelica Corcuera(University of Oxford), John Frater(University of Oxford), Veronica Miller(University of California, Berkeley), Timothy Peto, Wolfgang Stöhr(University College London), Alison Crook, Frank A. Post(King's College Hospital NHS Foundation Trust), Sarah Fidler(NIHR Imperial Biomedical Research Centre), Lucy Dorrell(MRC Human Immunology Unit), Darren B. Leneghan(Immunocore (United Kingdom)), Adam Gregory(John Radcliffe Hospital), Natalia Olejniczak, Maryam Khan, Matthew Pace, Eric Sandström(Stockholm South General Hospital), Johnson Mak(Griffith University), Anuska Llano(IrsiCaixa), Annette von Delft(University of Oxford), Mala K. Maini(California Institute of Technology), Otto Erlwein, Christian Brander(Universitat de Vic - Universitat Central de Catalunya), Nicola Ternette(University of Dundee), Christopher P. Conlon(University of Oxford), Abdel Babiker(MRC Clinical Trials Unit at UCL), Jakub Kopycinski(International HIV/AIDS Alliance), Steven Kaye, Nicola Robinson(University of Oxford), Janet Darbyshire(MRC Clinical Trials Unit at UCL), Myra O. McClure(Imperial College London)
Cell Reports
May 1, 2021
Cited by 4


Related Papers